Basilea Pharmaceutica (BSLN) Price & Analysis

Compare

2 Followers

BSLN Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF36.75 - CHF52.20

Previous CloseN/A

Volume30.09K

Average Volume (3M)36.71K

Market Cap

CHF569.85M

Enterprise ValueCHF693.80M

Total Cash (Recent Filing)CHF120.71M

Total Debt (Recent Filing)CHF111.67M

Price to Earnings (P/E)7.3

Beta1.00

Next Earnings

Aug 19, 2025

EPS Estimate

2.03

Last Dividend Ex-Date

Apr 11, 2013

Dividend YieldN/A

Share Statistics

EPS (TTM)4.70

Shares Outstanding13,314,145

10 Day Avg. Volume27,367

30 Day Avg. Volume36,713

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)-26.22

Price to Sales (P/S)0.00

P/FCF Ratio144.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF83.50

Price Target Upside78.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Basilea Pharmaceutica News

PremiumCompany Announcements

Basilea Pharmaceutica’s Fosmanogepix Study: A Potential Game-Changer in Pharma

4d ago

PremiumRatings

Buy Rating for Basilea Pharmaceutica Driven by Cresemba’s Global Success and Zevtera’s U.S. Rollout

28d ago

PremiumRatings

Positive Outlook for Basilea Pharmaceutica: Buy Rating Backed by Strong Product Launches and Market Position

2M ago

PremiumRatings

Basilea Pharmaceutica: Strong Buy Rating Backed by Zevtera’s U.S. Launch and Robust Financial Outlook

4M ago

See All CH:BSLN News

See All News >

Bulls Say, Bears Say

Bulls Say

Market ExpansionCeftobiprole was included in the National Reimbursement Drug List (NRDL), making it eligible for reimbursement under the Chinese national basic medical insurance program.

Product Sales PerformanceCresemba sales reach another pre-defined threshold, triggering a milestone payment.

Regulatory ApprovalsThe FDA approved Zevtera for three specific indications; it is the only FDA-approved methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin antibiotic for treating adult patients with S. aureus bloodstream infections (bacteremia) and endocarditis.

Bears Say

Market Penetration ChallengesRisks include potential challenges in market penetration for ceftobiprole in the U.S. and setbacks with clinical-stage candidates like fosmanogepix.

Partnership Optimization RisksRisks include inability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

2.99%

Mutual Funds

0.11% Other Institutional Investors

89.75% Public Companies and

Individual Investors

Detailed Ownership Overview >

BSLN FAQ

What was Basilea Pharmaceutica’s price range in the past 12 months?

Basilea Pharmaceutica lowest stock price was CHF36.75 and its highest was CHF52.20 in the past 12 months.

What is Basilea Pharmaceutica’s market cap?

Basilea Pharmaceutica’s market cap is CHF569.85M.

When is Basilea Pharmaceutica’s upcoming earnings report date?

Basilea Pharmaceutica’s upcoming earnings report date is Aug 19, 2025 which is in 43 days.

How were Basilea Pharmaceutica’s earnings last quarter?

Basilea Pharmaceutica released its earnings results on Feb 18, 2025. The company reported CHF4.7 earnings per share for the quarter, beating the consensus estimate of CHF3.24 by CHF1.46.

Is Basilea Pharmaceutica overvalued?

According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Basilea Pharmaceutica pay dividends?

Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here

What is Basilea Pharmaceutica’s EPS estimate?

Basilea Pharmaceutica’s EPS estimate is 2.03.

How many shares outstanding does Basilea Pharmaceutica have?

Basilea Pharmaceutica has 13,314,145 shares outstanding.

What happened to Basilea Pharmaceutica’s price movement after its last earnings report?

Basilea Pharmaceutica reported an EPS of CHF4.7 in its last earnings report, beating expectations of CHF3.24. Following the earnings report the stock price went up 8.323%.

Which hedge fund is a major shareholder of Basilea Pharmaceutica?

Currently, no hedge funds are holding shares in CH:BSLN

Company Description

Basilea Pharmaceutica

Basilea Pharmaceutica (BSLN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative pharmaceutical products to address the medical needs in the areas of oncology and infectious diseases. Based in Switzerland, Basilea's core products include a portfolio of treatments for bacterial infections and antifungal agents, as well as targeted cancer therapies. The company is committed to improving patient outcomes through the development of novel medicines that address drug resistance and provide new therapeutic options.

BSLN Stock 12 Month Forecast

Average Price Target

CHF83.50

▲(78.42%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"CHF34","101":"CHF101","50.75":"CHF50.8","67.5":"CHF67.5","84.25":"CHF84.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF83.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,50.75,67.5,84.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.6,49.784615384615385,53.96923076923077,58.15384615384616,62.338461538461544,66.52307692307693,70.70769230769231,74.8923076923077,79.07692307692308,83.26153846153846,87.44615384615385,91.63076923076923,95.81538461538463,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.6,48.51538461538462,51.43076923076923,54.34615384615385,57.261538461538464,60.176923076923075,63.09230769230769,66.00769230769231,68.92307692307692,71.83846153846153,74.75384615384615,77.66923076923078,80.58461538461538,{"y":83.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,45.6,47.246153846153845,48.892307692307696,50.53846153846154,52.184615384615384,53.830769230769235,55.47692307692308,57.12307692307692,58.769230769230774,60.41538461538462,62.06153846153846,63.70769230769231,65.35384615384615,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.6,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.3,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.65,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >